Headline EventAnalyzer: Weekly Market Movers (to 29 Jan 2010)
Source EP Vantage
Company Bavarian Nordic 
Related: Basilea Pharmaceutica, Cytori Therapeutics, Galapagos, GenVec, Gilead Sciences, Immunomedics, InterMune, mondoBIOTECH, Novo Nordisk, OncoTherapy Science, Poniard Pharmaceuticals, PT Kalbe Farma, Salix Pharmaceuticals, Theravance, Torrent Pharmaceuticals, Transgene, Zydus Cadila 
Date February 01, 2010
 

EvaluatePharma’s EventAnalyzer delivers a weekly global round up of key events driving company valuations.

Detailing the previous week’s top 15 market gains and losses, aligned with significant news flow driving share prices, the EventAnalyzer keeps you in touch with the latest market moves.

Top 15 Gains (%) - ranked on change in share price

      Performance: Fri 29 Jan vs. Fri 22 Jan   
Rank  Company  Listed Currency  Share Price Change  Market Cap (US$m)  Market Cap Change  Notes on Change 
1  International Stem Cells   USD  +61%  76  +31   
2  Bavarian Nordic   DKK  +26%  273  +56  27 Jan: Company settles a litigation suit with Oxford BioMedica over patents for  MVA-BN and grants rights to  Oxford BioMedica for  MVA-BN in return for milestone payments and royalties.  
3  InterMune   USD  +16%  838  +114  25 Jan: Shares rise on 2.5x average daily trading volume. 
4  Karo Bio   SEK  +15%  227  +29   
5  OncoTherapy Science   JPY  +14%  373  +45  26 Jan: Company raises its full-year revenue and earnings outlook due to an increase in orders. 
6  Incyte   USD  +13%  1266  +143   
7  PT Kalbe Farma   IDR  +12%  1656  +172  28 Jan: PT CIMB Securities Indonesia maintains "outperform" rating with a price target of Rp1,900 per share, stating that the company will benefit from the government's health insurance scheme. 
8  Zydus Cadila   INR  +10%  2089  +196  25 Jan [post market]: Company reports a 114% increase in Q3 net profit, beating expectations, driven mainly by formulation exports which grew by 45% and strong sales in the US and Europe. 
9  Torrent Pharmaceuticals   INR  +9%  804  +64  27 Jan [post market]: Company reports a 63.5% increase in consolidated Q3 net profit, helped by a 15% increase in formulations sales in India and a 10% increase in overseas sales. 
10  Galapagos   EUR  +8%  371  +28  29 Jan: Company expects to report its first full-year operating profit in 2010, a year earlier than expected. KBC maintains "buy" rating and price target of €10.50. 
11  Basilea Pharmaceutica   CHF  +8%  671  +50  29 Jan: An independent data safety monitoring board recommends that phase III trials for the company's anti-fungal treatment, isavuconazole, should continue after analysis shows that the drug is not inferior to the current standard of care, voriconazole; full phase III results will be available in 2011. 
12  Novo Nordisk   DKK  +7%  37533  +2475  25 Jan [post market]: Company receives FDA approval for its diabetes treatment, Victoza, however, more safety studies are required before the drug can be cleared as a first-line treatment. Cheuvreux maintains "outperform" rating and raises price target to DKK370 from DKK345. 
13  Transgene   EUR  +6%  746  +44  29 Jan: Shares rise on 3x average daily trading volume. 
14  Salix Pharmaceuticals   USD  +6%  1624  +112  26 Jan: Newman upgrades rating to "outperform" from "perform" with a price target of $40, stating that the FDA will approve the company's hepatic encephalopathy treatment Xifaxan, and also doubles its 2010 revenue forecast for the company to $0.46 per share.
  26 Jan: Oppenheimer upgrades rating to "outperform" from "perform". 
15  Gilead Sciences   USD  +5%  43439  +1970  26 Jan [post market]: Company's Q4 net profit rises 43% to $802.2m, beating consensus estimates, on strong sales of HIV drugs, Atripla and  Truvada, and on royalties from sales of Tamiflu; company also increases its 2010 sales forecast by 10%.  

Excludes companies with a market cap. movement of less than US$25m.

Top 15 Losses (%) - ranked on change in share price

      Performance: Fri 29 Jan vs. Fri 22 Jan    
Rank  Company  Listed Currency  Share Price Change  Market Cap (US$m)  Market Cap Change  Notes on Change 
1  GenVec   USD  -44%  201  -117  27 Jan: Company plans to raise $28m through the sale of 14m shares of common stock and warrants to buy 4.2m shares, at $2 per unit; each unit consists of one share of stock and 0.3 warrants to buy a share of stock. 
2  Poniard Pharmaceuticals   USD  -39%  67  -43  25 Jan: Phase II results for colorectal cancer drug, picoplatin, show that the drug meets its primary endpoint of a reduction in neurotoxicity compared to standard treatment oxaliplatin, in combination with chemotherapy, but also shows lower overall survival rates in patients and more occurrences of thrombocytopenia and neutropenia, raising concerns about the drug's safety and doubts about whether the company will be able to find a partner for the drug; multiple analysts downgrade ratings. 
3  mondoBIOTECH   CHF  -27%  189  -71  25 Jan: Company announces final terms of a rights issue to raise CHF43m ($40.6m), offering shareholders one new share and an option to buy one further share within three years, for CHF150.  
4  Immunomedics   USD  -23%  252  -75  26 Jan: Shares fall on 2.5x average daily trading volume. 
5  Theravance   USD  -19%  697  -160  28 Jan [post market]: The FDA notifies the company that its response to the Nov 2009 complete response letter for Vibativ, for the additional indication of nosocomial pneumonia, is incomplete and requires more data and may need further clinical studies.  
6  Cytori Therapeutics   USD  -18%  261  -58  22 Jan: Shares fall on 3x average daily trading volume on likely profit taking after touching a record high of $9.50. 
7  Lexicon Pharmaceuticals   USD  -14%  313  -52   
8  Eurand   EUR  -12%  498  -66   
9  Halozyme Therapeutics   USD  -11%  497  -64   
10  Cumberland Pharmaceuticals   USD  -10%  239  -28   
11  MicroBio   TWD  -10%  263  -31   
12  ll-Yang Pharmaceutical  KRW  -10%  304  -35   
13  LG Life Sciences   KRW  -10%  754  -85   
14  Questcor Pharmaceuticals   USD  -10%  291  -30   
15  Bukwang Pharmaceutical   KRW  -9%  321  -31   

Excludes companies with a market cap. movement of less than US$25m.

Disclaimer:
The above analysis is based on daily share prices supplied to EvaluatePharma Ltd by a third party. EvaluatePharma Ltd accepts no responsibility or liability for the accuracy of the data presented here. Neither should any data presented here be construed as a solicitation or offer to buy or sell any securities or related financial instruments.
 

This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
EP Vantage SM ©2010 EP Vantage Ltd